Skip to content
Buy This GLP
← Research
Evidence

CagriSema With Basal Insulin: HbA1c in a 274-Adult Phase 3 Trial

Added to basal insulin, cagrilintide-semaglutide cut HbA1c by 2.33 and 2.10 points at week 40, against 0.66 on placebo. The trial had no semaglutide-alone arm.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team6 min read
HbA1c fall at week 40, added to basal insulinCagriSema 2.4 mg each−2.33CagriSema 1.0 mg each−2.10placebo−0.66There was no semaglutide-alone arm to compare against.

The CagriSema weight-loss trials look at a different outcome. REIMAGINE 3 enrolled 274 adults with type 2 diabetes who were already taking basal insulin, with or without metformin. The main outcome was the change in HbA1c over 40 weeks [1].

Mean HbA1c started at 8.8%. The two CagriSema groups saw estimated declines of 2.33 and 2.10 percentage points, compared with 0.66 in the pooled placebo groups. Novo Nordisk funded the trial [1].

The trial recorded no severe hypoglycemia. Gastrointestinal symptoms made up most of the adverse events and were generally mild or moderate [1]. The guide to GLP-1 drugs and low blood sugar explains why insulin use matters when assessing that risk.

Novo Nordisk still described CagriSema as investigational in November 2026. The company submitted it to the FDA in December 2025 for weight management [2]. That filing covers a separate indication from the type 2 diabetes use studied here.

Frequently asked

Can I buy CagriSema?
CagriSema remained investigational in the United States as of November 2026.
Does adding cagrilintide to semaglutide help?
This trial cannot answer that. It compared the combination against placebo rather than against semaglutide alone, so it shows the combination works on top of insulin without isolating what cagrilintide contributes.
How large was the effect?
HbA1c fell 2.33 and 2.10 percentage points at the two dose levels against 0.66 on placebo, from a mean baseline of 8.8%, over 40 weeks in 274 participants.

Sources

  1. [1] Rosenstock J, Billings LK, Gajria R, Giorgino F, Johansen NB, Klein KR (2026). Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study The Lancet. PMID 42251856
  2. [2] Novo Nordisk (2026). Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial Novo Nordisk. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence